Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become central to diabetes and obesity treatment because of their strong effects on glucose reduction, weight loss, and cardiovascular protection. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.